Lipocine (LPCN) Interest Expenses (2011 - 2025)
Lipocine's (LPCN) quarterly Interest Expenses came in at $157200.0 in Q3 2025, up 1102.85% YoY from $13069.0 in Q3 2024, and down 37.5% on a QoQ basis from $251519.0 in Q2 2025.
Lipocine (LPCN) Interest Expenses (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Interest Expenses data on file, last reported at $157200.0 in Q3 2025.
- Quarterly Interest Expenses rose 1102.85% year-over-year to $157200.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$147710.0 (down 133.68% YoY) and the FY2024 annual result came in at $48.2 million, up 0.88% from the prior year.
- Interest Expenses retreated to $157200.0 in Q3 2025, from $251519.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $820904.0 in Q1 2021 to a low of $1315.0 in Q4 2023.
- A 5-year average of $271572.3 and a median of $230307.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 98.03% — and 2024, when it jumped 33255.51%.
- Tracing LPCN's Interest Expenses over 5 years: stood at $23873.0 in 2021, then jumped by 180.24% to $66902.0 in 2022, then sank by 98.03% to $1315.0 in 2023, then jumped by 33255.51% to $438625.0 in 2024, then tumbled by 64.16% to $157200.0 in 2025.
- The last three Interest Expenses figures came in at $157200.0 (Q3 2025), $251519.0 (Q2 2025), and $345839.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 157,200.00 |
| Sep 30, 2025 | 157,200.00 |
| Jun 30, 2025 | 251,519.00 |
| Jun 30, 2025 | 251,519.00 |
| Mar 31, 2025 | 345,839.00 |
| Mar 31, 2025 | 345,839.00 |
| Dec 31, 2024 | 438,625.00 |
| Dec 31, 2024 | 438,625.00 |
| Sep 30, 2024 | 13,069.00 |
| Sep 30, 2024 | 13,069.00 |
| Jun 30, 2024 | 230,307.00 |
| Jun 30, 2024 | 230,307.00 |
| Mar 31, 2024 | 37,261.00 |
| Mar 31, 2024 | 37,261.00 |
| Dec 31, 2023 | 1,315.00 |
| Dec 31, 2023 | 1,315.00 |
| Sep 30, 2023 | 148,898.00 |
| Sep 30, 2023 | 148,898.00 |
| Jun 30, 2023 | 238,237.00 |
| Jun 30, 2023 | 238,237.00 |